This page indexes companies developing sirtuin-targeted therapies for Parkinson's disease. Sirtuins (SIRT1-7) are NAD+-dependent deacetylases that play critical roles in mitochondrial function, stress resistance, and cellular homeostasis—all processes impaired in Parkinson's disease.
For the main mechanism page, see SIRT1 Activators for Parkinson's Disease.
- Direct SIRT1 activators (resveratrol, synthetic compounds)
- NAD+ precursors (nicotinamide riboside, NMN) that enhance SIRT1 activity indirectly
- PGC-1α deacetylation → mitochondrial biogenesis
- FOXO deacetylation → stress resistance
- α-synuclein deacetylation → reduced aggregation
- SIRT2 inhibitors reduce α-synuclein toxicity
- Protect dopaminergic neurons
- Improve motor function in PD models
- Mitochondrial sirtuin targeting
- SOD2 activation → reduced oxidative stress
- IDH2 activation → improved mitochondrial metabolism
| Company |
Focus |
Programs |
Page |
| GSK (GlaxoSmithKline) |
SIRT1 activators |
SRT2104 (historical), SRT3025 |
GSK |
| Company |
Focus |
Programs |
Page |
| ChromaDex |
NAD+ precursors |
NR-002 for Parkinson's |
ChromaDex |
| Life Biosciences |
SIRT1 activator |
LB-SIRT1 program |
Life Biosciences |
flowchart TD
subgraph Targets
A["SIRT1 Activation"] --> B["Mitochondrial Biogenesis"]
A --> C["Stress Resistance"]
A --> D["Aggregation Reduction"]
E["SIRT2 Inhibition"] --> F["α-Syn Protection"]
G["SIRT3 Activation"] --> H["ROS Reduction"]
end
subgraph Companies
B --> I["ChromaDex (NR)"]
C --> J["Life Biosciences"]
D --> J
F --> K["Preclinical pipeline"]
H --> L["Research stage"]
end
subgraph Products
I --> M["NR-002"]
J --> N["LB-SIRT1"]
end
| Company |
Compound |
Target |
Mechanism |
Phase |
Indication |
| ChromaDex |
NR-002 |
SIRT1 (indirect) |
NAD+ augmentation |
Phase 2 |
Parkinson's disease |
| GSK (historical) |
SRT2104 |
SIRT1 |
Direct activation |
Phase 2 |
Alzheimer's disease |
| Life Biosciences |
LB-SIRT1 |
SIRT1 |
Direct activation |
Discovery |
Alzheimer's/Parkinson's |
¶ Market Landscape
The sirtuin modulator field for Parkinson's disease has evolved through several phases:
- 2006-2012: Sirtris/GSK pioneered direct SIRT1 activators (resveratrol, SRT2104)
- 2012-2020: Shift to NAD+ precursors (nicotinamide riboside, NMN) as indirect activators
- 2020-present: Combination approaches and next-generation SIRT1 modulators
- Major pharma (GSK) has reduced direct SIRT1 activator investment
- Biotech focus on NAD+ augmentation (ChromaDex)
- Academic/industry partnerships for biomarker development
- Growing interest in SIRT2 inhibitors for PD
- Brain penetration: Current SIRT1 activators have limited CNS delivery
- Target engagement biomarkers: Need better biomarkers for SIRT1 activity
- Combination strategies: Sirtuin + other mechanisms (e.g., LRRK2, GBA)
- Genetic validation: Human genetic evidence for sirtuins in PD remains limited